94 reports

Global Brain Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Brain Cancer
  • Cancer
  • United States
  • World
  • Forecast

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • France
  • United States
  • Market Size

Europe Brain Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Brain Cancer
  • Europe
  • France
  • Germany
  • Forecast

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024 ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Catalyst ## ##. ## Related Reports ## ##. ## Upcoming Reports ## ## Epidemiology ## ##. ## Disease Background ##

  • Brain Cancer
  • Cancer
  • United States
  • World
  • Forecast

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • France
  • Germany
  • Italy
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • Japan
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • United States
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • France
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • Italy
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • Germany
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • United Kingdom
  • Market Size

Brain Cancer Phase ## Clinical Trials, 2016 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • Spain
  • Market Size

" Target Atlas in Brain Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline information covering commercial developments of molecular drug targets in brain cancer from ## companies

  • Brain Cancer
  • Cancer
  • Brain Cancer Treatment Drugs Sales Volume
  • Brain Cancer Treatment Drugs Sales Volume by Drugs Classification in 2017(percent)

China’s demand for Brain Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...

  • Brain Cancer
  • China
  • Demand
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd
  • Pricing Trend
  • Chapter IV

Some brain cancers occur when one type of cell transforms from its normal characteristics.

  • Brain Cancer
  • China
  • Demand
  • ACON Biotech Co., Ltd
  • Beijing Novartis Pharma Ltd
  • Brain Cancer Treatment Drugs Sales Volume by Drugs Classification in 2017(percent)
  • Market Size

This study focuses on China’s Brain Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....

  • Brain Cancer
  • China
  • ACON Biotech Co., Ltd
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

Increasing prevalence of cancer, brain tumours, and renal cell cancer will boost the market growth.

  • Brain Cancer
  • North America
  • United States
  • World
  • Guerbet Group
  • DESCRIPTION OF BRAIN CANCER TYPES
  • 4.5 EPIDEMIOLOGICAL FORECAST FOR BRAIN CANCER (2014-2024)

Opportunity Analyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024 Summary Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily...

  • Brain Cancer
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Tocagen Inc.

Healthcare Investor Conference 2017 ## Apr ##, 2017: FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer ## Apr ##, 2017: Novogen Update On Phase II Development Plans For GDC-## ## Mar ##, 2017: Blaze Bioscience Announces Tumor Paint BLZ-## Publication in In

  • Brain Cancer
  • Cancer
  • Clinical Trial
  • Drug Discovery And Development
  • World
  • 18.1 Competitive Scenario
  • 05. Introduction

Introduction Glioblastoma multiforme is a variant of brain cancer, and is one of the most aggressive diseases.

  • Brain Cancer
  • Arbor Pharmaceuticals, LLC
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.

Strategic initiatives List of Tables ##.

  • Brain Cancer
  • Therapy
  • United States
  • Forecast
  • Market Size

Brain Cancer Pipeline Highlights – 2017 ##.

  • Brain Cancer
  • Cancer
  • Pathology
  • United States
  • Product Initiative
  • Brain Cancer - Dormant Projects
  • Brain Cancer - Discontinued Products

Brain Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Brain Cancer - Pipeline Review, H2 2015’, provides an overview of the Brain Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis...

  • Brain Cancer
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.
  • Comprehensive Cancer Center, 2015* Trial Title
  • TREATING PATIENTS WITH PROGRESSIVE OR RECURRENT MALIGNANT GLIOMA

Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the...

  • Brain Cancer
  • World
  • Eisai Co., Ltd.
  • Insys Therapeutics, Inc.
  • Merck & Co., Inc.
  • JUN 23, 2015: CELLMID COLLABORATION TO TREAT BRAIN CANCER
  • OCT 05, 2016: CELLMID'S MIDKINE ANTIBODIES SHOW ANTI-TUMOR ACTIVITY AGAINST BRAIN CANCER

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H2 2017 Summary Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting...

  • Brain Cancer
  • World
  • Litigation And Patent
  • Product Initiative
  • Cellmid Limited
  • NANOTHERM - BRAIN CANCER
  • NANOTHERM - BRAIN CANCER - PRODUCT DESCRIPTION

Summary MagForce AG (MagForce) is a medical device company that offers nanotechnology-based cancer treatment. The company offers treatment for brain tumor and cancer diseases. It provides products such as NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. MagForce’s product NanoActivator creates a magnetic field that can be...

  • Brain Cancer
  • Germany
  • United States
  • Company
  • MagForce AG
  • JUN 23, 2015: CELLMID COLLABORATION TO TREAT BRAIN CANCER
  • OCT 05, 2016: CELLMID'S MIDKINE ANTIBODIES SHOW ANTI-TUMOUR ACTIVITY AGAINST BRAIN CANCER

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H1 2017 Summary According to the recently published report 'Midkine - Pipeline Review, H1 2017'; Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite...

  • Brain Cancer
  • World
  • Litigation And Patent
  • Product Initiative
  • Cellmid Limited
  • Sep 25, 2017: Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X- Rays
  • Sep 29, 2017: National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data...

  • Brain Cancer
  • Drug Discovery And Development
  • Oncology
  • World
  • Product Initiative
  • Novogen to Enter into Co-Development Agreement with Feinstein Institute for Medical Research for Brain Cancer
  • Novogen Enters into Licensing Agreement with Genentech for GDC-0084

Summary Kazia Therapeutics Ltd (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3-kinase (PI3K) inhibitors, anti-tropomyosins (ATM) and super-benzopyrans (SBP). ATM...

  • Brain Cancer
  • Australia
  • United States
  • M&A
  • Novogen Limited
  • May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
  • Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant

Pontine Glioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape. Pontine gliomas are highly aggressive and difficult to treat brain...

  • Brain Cancer
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company